Reformulary Group
Reformulary Group operates Canada's largest independent drug formulary, providing subscription-based evidence-based drug review tools and predictive analytics to 1,000+ Canadian organizations and 300,000+ covered lives through insurance carriers, benefits administrators, and direct enterprise sales.
- Company typePrivate
- Founded2011
- HeadquartersToronto, Canada
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Reformulary Group does
Reformulary Group Inc. is a Toronto-based, privately held Canadian health technology company founded in March 2011 by Helen Stevenson, a former Ontario Associate Deputy Minister of Health. The company builds and maintains "The Reformulary," described as the largest single independent drug formulary in Canada, which is based on over 300,000 hours of comparative drug reviews conducted by a standing Expert Committee of 14 physicians and clinical pharmacists meeting monthly since 2011. Its core functional offering is an evidence-based, portable drug list that organizations can subscribe to in order to manage prescription drug benefit costs while preserving plan member choice; the company reports over 300,000 covered lives across 1,000+ subscribing organizations.
The product stack centers on The Reformulary and is extended by a set of modules: DrugFinder (a consumer-facing app and desktop tool that searches the formulary, including an Amazon Alexa voice integration launched in 2018), the Drug Early Warning (DEW) System (predictive modeling for the impact of new high-cost drugs on plans, launched 2017), RePort (near real-time prescription claims analytics across public and private plans), meTrics (productivity and quality-of-life surveys tied to medication outcomes), myRequest (independent exception and appeal review services), and Cannabis Standard (cannabis-based medicine tracking launched 2018). Underlying technology components include clinical algorithms, predictive modeling on prescription claims data, and a Cinchy data fabric (partnership announced October 2020) for connecting data sources across the ecosystem.
The business operates a subscription-based revenue model, with organizations (employers, unions, associations) paying annual fees to access the formulary and tools, supplemented by professional services revenue from myRequest. Pricing is not publicly disclosed. Distribution is multi-channel: direct sales to HR and benefits administrators, integration into major Canadian insurance carriers (Sun Life Financial, Canada Life, The Co-operators, HUB International, ClaimSecure), channel partnerships with benefits administrators (Johnston Group, November 2021) and digital health platforms (Mednow, May 2023), an advisor/consultant portal, pharmacy distribution partners (Pillway, Rexall), and a self-serve consumer app (DrugFinder). The company is founder-led, has never disclosed an external funding round, and operates with a small 9-person team headquartered at 55 York Street, Suite 200, Toronto.
Reformulary Group firmographics
Firmographics- Name
- Reformulary Group
- Legal name
- Reformulary Group Inc.
- Website
- https://reformulary.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Reformulary Group operates Canada's largest independent drug formulary, providing subscription-based evidence-based drug review tools and predictive analytics to 1,000+ Canadian organizations and 300,000+ covered lives through insurance carriers, benefits administrators, and direct enterprise sales.
- Ownership category
- akta.pro rank
Reformulary Group industry classification
Industry- Product category
- Pharmacy Benefit Management
- akta.pro primary industry
- Pharmacovigilance, Medication Safety & Controlled Substance Diversion Monitoring (HLAFALAN)
- akta.pro secondary industries
- Value Dossier & Evidence Generation (AMCP/Global Value Dossier) (HLAIAKAC), Second Opinion & Expert Medical Review Platforms (HLALADAI), Pharmacovigilance & Drug Safety Software (HLAGAJAK)
Keywords
Where Reformulary Group is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Reformulary Group business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Subscription - Organization Access: Organizations (companies, unions, associations) subscribe to access The Reformulary drug list and associated tools (DrugFinder, RePort, meTrics) on a subscription basis. The formulary is made available to help plan members make smart drug choices and promote sustainable drug plans.
- Professional Services - myRequest: Independent exception, special authorization and appeal review services provided through the myRequest platform, staffed by Reformulary Group experts.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Subscription pricing for organizations (employers, unions, associations) |
Go-to-market motion2 records
Distribution channels6 records
Marketing channels8 records
Reformulary Group product offering
Product offeringCore offering
Reformulary Group curates an independent, evidence-based drug formulary (The Reformulary) built from over 300,000 hours of detailed drug reviews conducted by a 14-member expert committee of physicians and clinical pharmacists. The company makes this formulary and associated digital tools (DrugFinder, RePort, meTrics, myRequest, DEW System, Cannabis Standard) available to Canadian organizations on a subscription basis, helping employers, unions, and associations manage drug benefit costs and enable members to make informed medication choices.
Product overview
Reformulary Group operates as a platform-plus-modules architecture, with The Reformulary serving as the core proprietary drug formulary product. The main platform is complemented by four key modules: DrugFinder (mobile/desktop app for drug search), meTrics (productivity/quality-of-life surveys), RePort (business intelligence for prescription claims analytics), and myRequest (exception/appeal review services). Additional specialized offerings include the Drug Early Warning (DEW) System for predictive risk management and Cannabis Standard for cannabis-related drug tracking. The ecosystem is supported by an Expert Committee of 14 physicians and pharmacists providing clinical oversight.
Differentiator
Problem solved
Functional benefit
Brands
- The Reformulary: A portable formulary based on over 300,000 hours of detailed drug reviews with input from a panel of independent experts. Helps strike balance between cost savings and member health outcomes.
- DrugFinder
- meTrics
- RePort
- myRequest
- Cannabis Standard
Products and services
- The Reformulary A portable, evidence-based drug formulary based on over 300,000 hours of detailed drug reviews conducted by a panel of independent physicians and clinical pharmacists. It is the largest single independent drug formulary in Canada and is licensed to Canadian organizations (employers, unions, associations) on a subscription basis to help plan members make smart drug choices and promote sustainable drug plans.
- DrugFinder A mobile app and desktop tool, customized to each plan, that searches The Reformulary and enables plan members to make smart drug choices. Available on iOS, Android, and web, with first-in-Canada Amazon Alexa voice integration for conversational drug search.
- meTrics Survey tools developed to track productivity and quality-of-life outcomes related to a person's medications, allowing individuals to measure their own progress and outcomes.
- RePort A business intelligence tool providing near real-time insights on prescription claims for Canadians covered by both public and private drug plans, analyzing how comparable drugs are performing in the market.
- myRequest Fully independent exception, special authorization and appeal review service powered by Reformulary Group experts, providing trusted recommendations based on clinical evidence and plan member circumstances.
- Drug Early Warning (DEW) System A risk management tool that uses clinical algorithms and predictive modelling to project the impact of new high-cost drugs on drug plans, enabling proactive risk management for benefit plans.
- Cannabis Standard A formulary tool for cannabis-based medicines, including the Cannabis Standard Index introduced in 2020 to track cannabis and other medicines for patient-powered evidence.
Quantifiable outcome
- Over 15% savings on average in first year for employers
- +5 more outcomes
Companies that use Reformulary Group
Customer profileNamed customers10 records
Segments5 records
Ideal customer profiles3 records
Reformulary Group technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability2 records
Feature7 records
Reformulary Group partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and supporting.
- Mednow Inc.corePartnership to advance digital health solutions. Mednow is a digital health platform, and this collaboration integrates Reformulary's drug formulary expertise with Mednow's digital health services.
- Johnston GroupcoreJohnston Group, a leading Canadian benefits provider, offers the Reformulary to its Maximum Benefit clients across Canada. This partnership makes Reformulary available to Johnston Group's client base, expanding reach to more Canadian organizations seeking sustainable drug plan solutions.
- CinchysupportingData fabric platform partnership to accelerate how Reformulary connects its vast data sources across the prescription claims ecosystem. This partnership advances data collection and management capabilities.
- Productivity Tool Pilot PartnerssupportingPilot of productivity tool for cannabis and other medicines, expected to measure productivity and demonstrate effective medication outcomes.
- The Co-operatorscorePartnership agreement signed in 2014 to offer the Reformulary to The Co-operators' benefit plan clients.
- Sun Life FinancialcoreFirst major partnership agreement signed in 2011. Sun Life has integrated The Reformulary into their systems and markets it as 'the best solution in the market'. Sun Life offers industry-leading discounts on 'stop loss' charges for clients powered by Reformulary.
- Canada LifecoreInsurance company partner that has integrated The Reformulary into their systems for distribution to plan sponsor clients.
- HUB InternationalcoreMajor benefits advisor and insurance broker that has integrated The Reformulary into their offerings for client benefit plans.
- ClaimSecurecorePlan administrator partner that offers Reformulary-powered drug plans to their clients.
- PillwaysupportingDigital pharmacy platform partner shown in logos section, suggesting integration for prescription management.
- RexallsupportingPharmacy chain partner shown in logos section, suggesting pharmacy network integration.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Reformulary Group competitors and assessment
Company assessmentRegional players
- Loblaw Companies (Shoppers Drug Mart): Loblaw operates Shoppers Drug Mart, Canada's largest retail pharmacy chain, providing prescription drug services and pharmacist-led benefits management. Comparable to Reformulary as a Canadian pharmacy and drug plan touchpoint, though serving end consumers through retail rather than employer drug plans.
Broad incumbents
- Express Scripts (Cigna): Express Scripts is the largest U.S. pharmacy benefit manager (PBM), managing drug formularies for tens of millions of Americans. Comparable to Reformulary as a PBM/formulary operator, though it operates at vastly larger scale in the U.S. market and is part of broader Cigna healthcare services.
- Manulife Financial: Manulife is a major Canadian insurer offering group drug and health benefits to employers. Comparable to Reformulary in the employer drug benefits space, though Manulife operates its own proprietary formulary rather than partnering with an independent provider like Reformulary.
- OptumRx (UnitedHealth Group): OptumRx is one of the largest U.S. PBMs, providing drug formulary management and pharmacy services to employer-sponsored health plans. Comparable to Reformulary as a formulary operator for employer plans, though it operates as part of UnitedHealth's broader integrated payer-provider-PBM stack.
- CVS Caremark: CVS Caremark is a major U.S. PBM operating within CVS Health, providing drug formulary and pharmacy benefit services to employer plans. Comparable to Reformulary as a PBM/formulary operator, though bundled into a vertically integrated retail pharmacy and healthcare services company.
Direct peers
- Medavie Blue Cross: Medavie Blue Cross is a Canadian health benefits carrier serving employer, government, and individual drug and health plans. Directly comparable to Reformulary as a Canada-focused benefits provider competing for the same employer/union/association drug plan customers.
- Telus Health: Telus Health is a Canadian health benefits management and virtual care provider offering employer drug and health benefit plans. It is directly comparable to Reformulary as a Canadian health IT platform serving employer drug plans, though it operates at significantly larger scale with broader service offerings.
- GreenShield Canada: GreenShield is a Canadian not-for-profit health benefits carrier serving employers, unions, and associations with drug, dental, and health benefit plans. Comparable to Reformulary as a Canada-focused health benefits provider with employer and association distribution channels and proprietary drug management tools.
Emerging players
- Pillway: Pillway is a Canadian digital pharmacy platform offering prescription management and delivery. A Reformulary technology partner, comparable as an emerging player integrating prescription management with formulary content for plan members.
- Mednow: Mednow is a Canadian digital health platform offering virtual pharmacy and drug delivery. Reformulary's distribution partner, comparable as an emerging Canadian digital health player integrating pharmacy and formulary services for consumers and employer plans.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Reformulary Group social profiles
Digital presenceReformulary Group compliance and trust
Trust signalCompliance3 records
Reformulary Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Reformulary Group leadership team
Management profileNumber of profiles
Profiles10 records
Reformulary Group funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Reformulary Group M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Reformulary Group
What does Reformulary Group do?
Reformulary Group curates an independent, evidence-based drug formulary (The Reformulary) built from over 300,000 hours of detailed drug reviews conducted by a 14-member expert committee of physicians and clinical pharmacists. The company makes this formulary and associated digital tools (DrugFinder, RePort, meTrics, myRequest, DEW System, Cannabis Standard) available to Canadian organizations on a subscription basis, helping employers, unions, and associations manage drug benefit costs and enable members to make informed medication choices.
Is Reformulary Group a public or private company?
Reformulary Group is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Reformulary Group founded?
Reformulary Group was founded in 2011. It employs 11 to 50 people.
Where is Reformulary Group based?
Reformulary Group is headquartered in Toronto, Canada, in the North America region.
How does Reformulary Group make money?
Two revenue lines are on record. Subscription - Organization Access are the primary driver. The others are professional Services - myRequest.
Who are Reformulary Group's main competitors?
Loblaw Companies (Shoppers Drug Mart) is listed as a regional player. Broad incumbents are Express Scripts (Cigna), Manulife Financial, OptumRx (UnitedHealth Group) and CVS Caremark. Direct peers are Medavie Blue Cross, Telus Health and GreenShield Canada. Emerging players are Pillway and Mednow.
Does Reformulary Group have an API?
No public API is recorded for Reformulary Group.
What industry is Reformulary Group in?
Reformulary Group's product category is Pharmacy Benefit Management. Its primary akta.pro industry code is HLAFALAN, Pharmacovigilance, Medication Safety & Controlled Substance Diversion Monitoring, with a secondary code of HLAIAKAC, Value Dossier & Evidence Generation (AMCP/Global Value Dossier).